Loading
Latest filing published 13 Feb 2026 for Lineage Cell Therapeutics, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
George A. Samuel III is a declared insider of Lineage Cell Therapeutics, Inc., with filings sourced from SEC (Form 4). The record holds 11 filings, for trades running from 11 February 2023 to 11 February 2026.
Every open-market trade on record is a purchase: 1 purchase worth €8,617, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 6 share grants and 4 option exercises.
The newest entry dates from 13 February 2026: a share grant of €3,788, in Lineage Cell Therapeutics, Inc. The most recent open-market purchase was published on 26 November 2024, 697 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations